XOMA Royalty (NASDAQ:XOMA) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
XOMA Royalty (NASDAQ:XOMA) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
XOMA Royalty (NASDAQ:XOMA) was upgraded by analysts at
Weiss Ratings from a "sell (d-)" rating to a "hold (c-)" rating.
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements